HBeAg-positive patients with HBsAg < 100 IU/mL and negative HBV RNA have lower risk of virological relapse after nucleos(t)ide analogues cessation - Xie, Yandi; Li, Minghui; Ou, Xiaojuan; Zheng, Sujun; Gao, Yinjie; Xu, Xiaoyuan; Yang, Ying; Ma, Anlin; Li, Jia; Huang, Yuan; Nan, Yuemin; Zheng, Huanwei; et al. (Journal of gastroenterology, 2021)
Keywords: Abdominal Surgery; Adult; Antigens; Antiviral Agents - therapeutic use; Biliary Tract; China - epidemiology; Cohort Studies; Colorectal Surgery; Female; Gastroenterology; Hepatitis B; Hepatitis B - drug therapy; Hepatitis B - epidemiology; Hepatitis B e antigen; Hepatitis B e Antigens - analysis; Hepatitis B e Antigens - classification; Hepatitis B surface antigen; Hepatitis B virus - pathogenicity; Hepatology; Humans; Logistic Models; Male; Medicine; Medicine & Public Health; Middle Aged; Original Article―Liver; Original ―Liver, Pancreas, and Biliary Tract; Pancreas; Patients; Prospective Studies; Recurrence; Ribonucleic acid; RNA; Surgical Oncology; Treatment Outcome; China; HBcrAg; Virological relapse; Cessation; HBsAg loss; HBV RNA